Nantahala Capital Management, LLC has disclosed a substantial stake in Curis, Inc., revealing that it owns 9.99% of the company’s common stock. This move is significant as it underscores Nantahala's growing influence in the biological products sector, which is characterized by firms engaged in the development of biological products.

The filing, submitted on November 13, 2026, indicates that Nantahala may be deemed the beneficial owner of 258,739 shares of Curis, Inc., held by funds and separately managed accounts under its control. This stake includes shares that may be acquired within sixty days through the exercise of convertible securities.

Background

Nantahala Capital Management, LLC is an investment management firm based in New Canaan, Connecticut. The firm specializes in managing funds and separately managed accounts, focusing on various investment strategies. Curis, Inc., the company in which Nantahala has acquired a stake, is classified under the SIC code for biological products (no diagnostic substances), highlighting its role in the life sciences industry.

What the Filing Says

The filing states, "As of September 30, 2026, Nantahala may be deemed to be the beneficial owner of 258,739 Shares held by funds and separately managed accounts under its control." This stake represents a significant portion of Curis's outstanding shares.

Impact

This development may affect various stakeholders, including shareholders of Curis, potential investors, and competitors in the biological products sector. With Nantahala holding nearly 10% of Curis, its decisions could influence the company’s strategic direction and operational decisions.

What's Next

The filing does not say what happens next.